



Northern Health August Formulary Update

Effective August 16, 2019

New and Updated Formulary-Restricted Medications:

- rifAXIMin tablets (Zaxine®): restricted to the management of overt hepatic encephalopathy (HE) in combination with the maximum tolerated dose of lactulose.
- empagliflozin tablets (Jardiance®): restricted to the treatment of type 2 diabetes mellitus after inadequate glycemic control on maximum tolerated doses of dual therapy of metformin AND a sulfonylurea OR intolerance to a sulfonylurea.
- BCCA Additions: restricted to indications outlined in the BCCA Benefit Drug List AND patients who are registered with BCCA,
 - alectinib capsules (Alecensaro®)
 - avelumab injectable (Bavencio®)
 - mechlorethamine gel (Legada®)
- ticagrelor (Brilinta®): updated to include physicians who have prescribed ticagrelor to patients who meet Pharmacare Special Authority criteria but are not listed on the Collaborative Prescribing Agreement.

Removed Therapeutic Interchange:

- etidronate + calcium (Didrocal® kit) TIP: removal of TIP secondary to discontinuation of etidronate tablets from the Canadian market.

Medications Excluded from Formulary:

- insulin degludec (Tresiba®)

Discontinued Medications:

- clodronate 60 mg/mL X 5 mL injectable (Ostac®)
- etidronate + calcium (Didrocal®) kit and etidronate tablets (Didronel®)
- fluphenazine decanoate injectable (Modecate®)
- nitroglycerin topical ointment (Nitrol®)

August 16, 2019 For the information of physicians, nurses and pharmacists PLEASE POST	Formulary Changes	✓	For further information contact: <i>Jessica Brecknock *or* Ryan Doerksen</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		